Scientific program
| Satellite symposia
Home > Scientific program
| Breakfast Symposium - Takeda / Novartis | Saturday, September 10th(07:30-08:30) – Grand Ballroom A+B+C(3F) Chairperson : Hyun Jae Kang |
 |
Sang Yeol Lee Kyung Hee University, Korea |
(Takeda) The Optimized DPP4 Inhibitor in Treatment of T2DM Patients with Atherogenic Risk |
|
Kwang Joon Kim Yonsei University, Korea |
(Novartis) DM and NAFLD – The Role of Vildagliptin |
| Luncheon Symposium 1- MSD | Friday, September 9th(11:50-13:20) – Grand Ballroom A+B+C(3F) Chairperson : Bong Soo Cha |
|
Kyung Woo Park Seoul National University, Korea |
(MSD) Beyond Statin Monotherapy : Benefit of Atozet(ezetimibe/atorvastatin) in High Risk Patients |
| Luncheon Symposium 2 – AstraZeneca | Saturday, September 10th(11:50-13:20) – Grand Ballroom A+B+C(3F) Chairperson : Hyeong Joon Yoo |
 |
Stephen Nicholls Royal Adelaide Hospital, Australia |
Triglyceride Rich Lipoproteins: The Next Frontier in Atherosclerosis? |
|
Yong-ho Lee Yonsei University, Korea |
Benefit Your T2DM Patients by Early Initiation of Metformin/SGLT-2I Combination Treatment |
